Cost-effectiveness of primarily human papillomavirus–based cervical cancer screening in settings with currently established Pap screening: A systematic review commissioned by the German Federal Ministry of Health
- 9 April 2008
- journal article
- review article
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 24 (2), 184-192
- https://doi.org/10.1017/s0266462308080264
Abstract
Objectives:The aim of this study was to summarize the current evidence for the cost-effectiveness of primarily human papillomavirus (HPV) -based cervical cancer screening in settings with already established Papanicolaou test (Pap) programs. Emphasis was placed on the German situation with annual Pap screening.Methods:Medical, economic, and health technology assessment (HTA) databases were systematically searched for cost-effectiveness studies comparing HPV to Pap screening. Study data were extracted, standardized, and summarized in cost-effectiveness plots contrasting HPV strategies to Pap screening with 1-, 2-, 3-, and 5-years interval. For each Pap setting, the likelihood of cost-effective HPV screening was assessed depending on willingness-to-pay.Results:We reviewed twelve decision-analytic cost-effectiveness models. Study results showed wide variation due to methodical heterogeneity. Data synthesis revealed that the cost-effectiveness of HPV screening depends on the interval of the established Pap screening strategy. In comparison with Pap screening every 2 years, only 25 percent of the HPV-based screening strategies were cost-effective. However, in comparison with Pap screening every 1, 3, or 5 years, 83 percent, 55 percent, and 92 percent of HPV screening strategies were cost-effective, respectively. Results for settings with annual Pap screening are based on models assuming 100 percent screening coverage.Conclusions:The introduction of HPV-based screening programs is cost-effective if the screening interval of the established Pap program exceeds 2 years. In settings with biennial Pap screening, introduction of HPV-based screening is unlikely to be cost-effective. Results also suggest cost-effectiveness of HPV-based screening in settings with annual Pap screening; however, this finding should be confirmed under realistic screening adherence assumptions.Keywords
This publication has 24 references indexed in Scilit:
- Cost-effectiveness of Human Papillomavirus DNA Testing in the United Kingdom, The Netherlands, France, and ItalyJNCI Journal of the National Cancer Institute, 2005
- The cost-effectiveness of human papillomavirus screening for cervical cancerThe European Journal of Health Economics, 2005
- Cost-Effectiveness of Human Papillomavirus DNA Testing for Cervical Cancer Screening in Women Aged 30 Years or MoreObstetrics & Gynecology, 2004
- Economic evaluation of human papillomavirus screening in GermanyThe European Journal of Health Economics, 2003
- Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patientsBritish Journal of Cancer, 2003
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- Zur Wirtschaftlichkeit von Qualitätsverbesserungsmaßnahmen im GesundheitswesenMedizinische Klinik - Intensivmedizin und Notfallmedizin, 2002
- HPV testing in primary screening of older womenBritish Journal of Cancer, 1999
- The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of cervix uteriObstetrics & Gynecology, 1995
- Audit of deaths from cervical cancer: proposal for an essential component of the National Screening Programme.Journal of Clinical Pathology, 1994